In the past three months, J&J’s (JNJ) stock has risen 12.8% compared with an increase of 11.4% for the industry. J&J has also outperformed the sector as well as the S&P 500 in the same timeframe. J&J’s stock has also been trading above its 200-day and 50-day moving averages since mid-July.JNJ Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchMost of the stock’s outperformance was related to J&J’s strong second-quarter results, wherein it beat estimates for both earnings and ...

Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved its lung cancer drug Rybrevant (amivantamab) for expanded use.The EC approved a type II extension of indication for Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions after failure of prior therapy, including an EGFR tyrosine kinase inhibitor (TKI).JNJ's Stock PerformanceShares of JNJ have increa ...

IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on ... [+] October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesWe believe that Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Procter & Gamble stock (NYSE: PG) as it appears to show more promise over the coming years. T ...

Johnson & Johnson (JNJ) announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), harboring susceptible FGFR3 genetic alterations.The drug has been approved for UC patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.UC is the most common type of bladder cancer. Europe has the highest rate of b ...

These stocks have quality businesses behind them.Some investors might be feeling the brunt of stock market volatility as concerns about inflation persist. The last several years have been a bumpy ride, that's for certain.If you're focused on the long term, you should be holding stocks of great companies that can weather the storm. You should hang on to them for several years at minimum but more likely a decade or more. And if you're only putting your cash into quality companies that you're comfortable with ...

Nudphon Phuengsuwan Introduction I started covering Johnson & Johnson (NYSE:JNJ) in September of last year, when the stock became interesting again, as spin-off and lawsuit headlines provided several buyable corrections. As we can see below, I have written about this company three times. All of my calls are profitable - yet not by a lot. My most recent article was published on March 28, when I focused on its transition to high-growth healthcare markets. Since then, shares have returned 3.5%, lagging the 6% ...

patpitchaya/iStock via Getty Images JNJ stock: buy rating reiterated It was about three months ago that I last analyzed Johnson & Johnson (NYSE:JNJ) stock. As the following screenshot shows, my last article was titled "Johnson & Johnson: Market Will Regret The Overreaction" and rated the stock as a buy. The article argued that recent price corrections were an overreaction to the temporary issues the stock has been facing such as the talc-related bankruptcy filings and the Stelara patent expiration. Quote: T ...

This leading pharmaceutical stock is flying under the radar right now.Eli Lilly (LLY 0.21%) is hogging the headlines as its market capitalization marches toward $1 trillion. But even as the market continues to evaluate the growing demand for anti-obesity drugs and bids up businesses in the weight-loss space, it could be ignoring other businesses in the pharma industry. As a result, quite a few pharmaceutical stocks are currently flying under the market's radar, and investors could be looking at solid opport ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $161.43, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.57%.Shares of the world's biggest maker of health care products witnessed a gain of 5.13% over the previous month, beating the performance of the Medical sector with its gain of 4.9% and the S&P 500's gain of 1.77%.Market par ...

Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire a privately held medical device company, V-Wave Ltd., for an initial upfront payment of $600 million.V-Wave is engaged in developing innovative treatment options for treating heart failure.With this acquisition, JNJ is looking to add V-Wave's novel implantable device, the Ventura Interatrial Shunt (IAS), a minimally invasive device to treat heart failure with reduced ejection fraction (HFrEF). The Ventura IAS has re ...